Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

PURPOSE: We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. METHODS: Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacok...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Clin Pharmacol
Hlavní autoři: Larson, Richard A., Yin, Ophelia Q. P., Hochhaus, Andreas, Saglio, Giuseppe, Clark, Richard E., Nakamae, Hirohisa, Gallagher, Neil J., Demirhan, Eren, Hughes, Timothy P., Kantarjian, Hagop M., le Coutre, Philipp D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557053/
https://ncbi.nlm.nih.gov/pubmed/22207416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-011-1200-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky